Please login to the form below

Not currently logged in

EMA launches rolling review of J&J’s COVID-19 vaccine

Vaccine entered phase 3 testing in September

Johnson & Johnson's (J&J) investigational COVID-19 vaccine candidate has begun a rolling submission by the European Medicines Agency (EMA).  

The EMA has launched a rolling review the vaccine candidate, based primarily on positive non-clinical data demonstrating that the vaccine produces a ‘robust’ immune response.

This rolling review will enable the EMA to accelerate the assessment of J&J’s vaccine by allowing the agency to review data as and when it becomes available.

When the EMA’s human medicines committee (CHMP) determines that it has sufficient data, J&J can then submit a formal application for approval of the vaccine within the European Union.

J&J is also in talks with other global health regulatory authorities as it preps regulatory review processes for the COVID-19 vaccine to be used during the pandemic response period.

The investigational candidate uses J&J’s AdVac vaccine platform, which was also used to develop the company’s approved Ebola vaccine regimen, as well as additional investigational vaccines for the Zika virus, RSV and HIV.

In September, J&J advanced the vaccine into phase 3 testing, following positive interim results from a phase 1/2a trial of the shot.

In an interim analysis of results from the ENSEMBLE phase 1/2a trial, J&J’s vaccine demonstrated a promising safety profile and immunogenicity after a single dose.

The pharma giant is initiating the phase 3 ENSEMBLE trial in collaboration with the US Department of Health and Human Services’ (HHS), Biomedical Advanced Research and Development Authority (BARDA) and the US National Institute of Allergy and Infectious Diseases (NIAID).

In a separate principle agreement, J&J will also collaborate with the UK government on a phase 3 clinical trial in multiple countries to explore a two-dose regimen of its COVID-19 vaccine candidate.

A number of COVID-19 vaccine candidates are now seeking regulatory approval through similar rolling review processes, including those from Pfizer/BioNTech, Moderna and AstraZeneca.

Pfizer/BioNTech’s mRNA-based COVID-19 vaccine is the first among these to have received emergency use authorisation, after scoring approval from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) today.

Article by
Lucy Parsons

2nd December 2020

From: Regulatory



PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs


Add my company
Page & Page and Partners

For those who can imagine better, Page & Page and Partners (P&P) is home to meaningful encounters of a marketing, communication...

Latest intelligence

Patient recruitment and retention 2021 state of play
At COUCH Health, we’ve recently done some social listening to look into the discussions around ‘patient recruitment’ and ‘patient retention’, to see if these conversations have been impacted by the...
The UK has approved the first vaccine for COVID-19. What now?
The authorisation of Pfizer/BioNtech's mRNA vaccine by the MHRA is great news, but no-one has ever tried to roll out a vaccine as rapidly as this one, so we have...
Clinical trials and the diversity principle
If they were ever really hidden, 2020 revealed the expensive-sounding problems limiting diversity in clinical trials. Solutions are overdue....